lifestyle.eastmnweeklynews.com

Author: Erasca, Inc.

Erasca Reports First Quarter 2026 Business Updates and Financial Results

May 11, 2026
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

May 11, 2026
Erasca to Present at the Bank of America Securities Health Care Conference

May 6, 2026
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

April 27, 2026
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

April 27, 2026
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

March 12, 2026
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

March 10, 2026
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

March 5, 2026
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

February 24, 2026
Erasca to Present at Upcoming Conferences in February

February 11, 2026